Accum™ Technology: A Novel Conjugable Primer for Onco-Immunotherapy
Sign Up to like & getrecommendations! Published in 2022 at "Molecules"
DOI: 10.3390/molecules27123807
Abstract: Compromised activity is a common impediment for biologics requiring endosome trafficking into target cells. In cancer cells, antibody-drug conjugates (ADCs) are trapped in endosomes or subsequently pumped extracellularly, leading to a reduction in intracellular accumulation.… read more here.
Keywords: novel conjugable; immunotherapy; onco immunotherapy; accum technology ... See more keywords